The IP and Commercialisation team has a range of opportunities including patented technologies, software, data and know-how which is offered for commercialisation use under licences or to develop partnership and collaboration opportunities.
Print structures directly in living tissue via minimally invasive procedure. 3D cell-printed structures can be used for research models, drug delivery and discovery, and toxicology. Structures can also be used for bioelectronic devices and central nervous system stimulation
PeroxiPlat is a molecular Fluorescence Probe for Peroxisomes. It offers unique opportunities in diagnostic applications as it is non-disruptive to cell functionality.
A novel way of analysing conventional EEG signals to identify EEG parameters that is indicative of Autism Spectrum Disorder (ASD).
Modified peptides and peptide-liposomes that bind to Tau and inhibit its aggregation into neurofibrillary tangles. They could be useful for the prevention and/or treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases.
A new technique has been developed to deposit high crystalline quality Gallium Antimonide (GaSb) epilayers on low-cost Silicon substrates.
New gesture control technology that can turn everyday objects into remote controls could revolutionise how we interact with devices.
Telecoms-wavelength vertical-cavity surface-emitting lasers (VCSELs) capable of operating at up to 110°C with high wavelength stability and low threshold currents.
Please contact:
Jessica Wenmouth, Commercialisation Impact Manager
Maire Nolan, Head of Research and Enterprise Contracts
